Historical Valuation
OS Therapies Inc (OSTX) is now in the Fair zone, suggesting that its current forward PS ratio of 47.19 is considered Fairly compared with the five-year average of -5.57. The fair price of OS Therapies Inc (OSTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.60
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
OS Therapies Inc (OSTX) has a current Price-to-Book (P/B) ratio of 12.26. Compared to its 3-year average P/B ratio of -17.06 , the current P/B ratio is approximately -171.86% higher. Relative to its 5-year average P/B ratio of -17.06, the current P/B ratio is about -171.86% higher. OS Therapies Inc (OSTX) has a Forward Free Cash Flow (FCF) yield of approximately -27.30%. Compared to its 3-year average FCF yield of -15.16%, the current FCF yield is approximately 80.04% lower. Relative to its 5-year average FCF yield of -15.16% , the current FCF yield is about 80.04% lower.
P/B
Median3y
-17.06
Median5y
-17.06
FCF Yield
Median3y
-15.16
Median5y
-15.16
Competitors Valuation Multiple
AI Analysis for OSTX
The average P/S ratio for OSTX competitors is 8.63, providing a benchmark for relative valuation. OS Therapies Inc Corp (OSTX.A) exhibits a P/S ratio of 47.19, which is 446.52% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for OSTX
1Y
3Y
5Y
Market capitalization of OSTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OSTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is OSTX currently overvalued or undervalued?
OS Therapies Inc (OSTX) is now in the Fair zone, suggesting that its current forward PS ratio of 47.19 is considered Fairly compared with the five-year average of -5.57. The fair price of OS Therapies Inc (OSTX) is between to according to relative valuation methord.
What is OS Therapies Inc (OSTX) fair value?
OSTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of OS Therapies Inc (OSTX) is between to according to relative valuation methord.
How does OSTX's valuation metrics compare to the industry average?
The average P/S ratio for OSTX's competitors is 8.63, providing a benchmark for relative valuation. OS Therapies Inc Corp (OSTX) exhibits a P/S ratio of 47.19, which is 446.52% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for OS Therapies Inc (OSTX) as of Jan 10 2026?
As of Jan 10 2026, OS Therapies Inc (OSTX) has a P/B ratio of 12.26. This indicates that the market values OSTX at 12.26 times its book value.
What is the current FCF Yield for OS Therapies Inc (OSTX) as of Jan 10 2026?
As of Jan 10 2026, OS Therapies Inc (OSTX) has a FCF Yield of -27.30%. This means that for every dollar of OS Therapies Inc’s market capitalization, the company generates -27.30 cents in free cash flow.
What is the current Forward P/E ratio for OS Therapies Inc (OSTX) as of Jan 10 2026?
As of Jan 10 2026, OS Therapies Inc (OSTX) has a Forward P/E ratio of -2.53. This means the market is willing to pay $-2.53 for every dollar of OS Therapies Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for OS Therapies Inc (OSTX) as of Jan 10 2026?
As of Jan 10 2026, OS Therapies Inc (OSTX) has a Forward P/S ratio of 47.19. This means the market is valuing OSTX at $47.19 for every dollar of expected revenue over the next 12 months.